Encoraf 75 mg (Encorafenib) Tablets

Introduction

Encoraf 75 mg (Encorafenib) is a highly potent, targeted oncology medication classified as a small-molecule BRAF kinase inhibitor. Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Onco Solution, Encoraf represents a critical milestone in precision medicine. It is specifically designed to target the mutated BRAF V600E protein, which acts as an unregulated accelerator for cancer cell replication. When utilized in rational combination regimens, Encoraf shuts down hyperactive intracellular signaling pathways, offering a powerful, targeted alternative to standard chemotherapy for aggressive malignancies.

Indications

Encoraf 75 mg (Encorafenib) is indicated for:

• Metastatic Colorectal Cancer (mCRC): In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an approved companion diagnostic test, after prior systemic therapy.
• Unresectable or Metastatic Melanoma: In combination with binimetinib (such as Binixen), for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
• Limitations of Use: Encoraf is not indicated for the treatment of patients with wild-type BRAF cancers.

Pharmacology

Encorafenib, the active ingredient in Encoraf, is an oral, small-molecule kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in-vitro cell-free assays.

• Mechanism of Action: Mutations in the BRAF gene (predominantly V600E) result in constitutively active BRAF kinases that continuously stimulate the downstream MAPK signaling pathway (RAF-MEK-ERK), driving rapid tumor cell proliferation and survival.
• Combination Synergism: Encorafenib binds to the mutated kinase to halt this pathway. When used in colorectal cancer, blocking BRAF often causes a feedback reactivation of EGFR; pairing Encoraf with an anti-EGFR monoclonal antibody like cetuximab creates a dual-node blockade that prevents resistance and dramatically increases cancer cell apoptosis (cell death).

Dosage & Administration

Oral Administration for Adults:

• Metastatic Colorectal Cancer Dose: The standard dose is 300 mg (four 75 mg capsules/tablets) taken orally once daily in combination with cetuximab, until disease progression or unacceptable toxicity.
• Metastatic Melanoma Dose: When paired with binimetinib, the standard dose is 450 mg (six 75 mg capsules/tablets) taken orally once daily.
• Administration Guide: Can be taken with or without food at approximately the same time each day.
• Method: Swallow the tablets/capsules whole with a glass of water. Do not open, crush, or chew them.
• Missed Dose: If a dose is missed by more than 12 hours, skip that dose and take the next dose at the regularly scheduled time. Do not take a double dose.

Drug Interactions

• Strong or Moderate CYP3A4 Inhibitors: Concomitant use (e.g., Ketoconazole, Clarithromycin, Grapefruit juice) increases encorafenib exposure, elevating the risk of severe toxicity. Avoid co-administration; if unavoidable, implement strict dose reductions.
• Strong or Moderate CYP3A4 Inducers: Avoid co-administration (e.g., Rifampin, Carbamazepine) as they significantly decrease Encoraf plasma levels and reduce therapeutic efficacy.
• OATP1B1/3 Substrates: Encorafenib may increase the concentration of drugs that are substrates of these transporters (e.g., certain statins).

Contraindications

• Hypersensitivity: Known severe hypersensitivity or systemic allergic reaction to Encorafenib or any inactive excipients in the formulation.
• Pregnancy: Categorized as a known risk to embryo-fetal development.

Side Effects

Patients receiving Encoraf 75 mg in combination regimens may experience:

• Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, and decreased appetite.
• Dermatological: Rash, dry skin, pruritus (itching), hyperkeratosis, and hand-foot skin reaction (palmar-plantar erythrodysesthesia).
• Systemic: Fatigue, pyrexia (fever), arthralgia (joint pain), and myalgia (muscle pain).
• Ocular: Visual disturbances, including uveitis, iritis, or blurred vision.
• Secondary Malignancies: Increased risk of developing cutaneous squamous cell carcinoma (cuSCC) or new primary melanomas (monitored closely via regular skin exams).

Pregnancy & Lactation

• Pregnancy: Can cause severe fetal harm. Females of reproductive potential must verify negative pregnancy status before initiation and utilize effective non-hormonal contraception during therapy and for at least 2 weeks after the final dose.
• Lactation: Breastfeeding is discouraged during treatment and for at least 2 weeks after the last dose to prevent structural risks to the infant.

Precautions & Warnings

• New Primary Malignancies: Cutaneous and non-cutaneous malignancies can occur. Perform dermatologic evaluations prior to initiating therapy, every 2 months during treatment, and for up to 6 months post-discontinuation.
• Hepatotoxicity: Monitor liver function tests (ALT, AST, Bilirubin) before starting treatment and at least monthly during therapy.
• Cardiac Effects (QT Prolongation): Assess ECG and electrolytes prior to and during treatment. Correct hypokalemia or hypomagnesemia before administering Encoraf.
• Ophthalmic Toxicities: Monitor closely for visual changes. Withhold treatment if uveitis or serious retinal detachments occur.

Use in Special Populations

• Hepatic Impairment: Encorafenib is primarily metabolized by the liver. Use with caution in patients with mild hepatic impairment; it is not recommended for moderate-to-severe hepatic disease.
• Pediatric Use: Safety and effectiveness in pediatric patients under 18 years of age have not been established.

Overdose Effects

Overdose can result in severe dermatological toxicity, profound gastrointestinal distress, or life-threatening QT interval prolongation. Treatment requires immediate clinical evaluation, drug suspension, and aggressive supportive care.

Storage

• Condition: Store at controlled room temperature (15°C to 30°C).
• Protection: Keep the medication sealed in its original moisture-resistant packaging. Protect from direct heat, humidity, and sunlight. Keep safely out of reach of children.

Supplier Information

Onco Solution is an established premier global oncology medicine supplier dedicated to bridging gaps in advanced global cancer care. We ensure the secure, reliable, and temperature-controlled distribution of cutting-edge targeted treatments like Encoraf 75 mg. For clinical pricing quotes or international export inquiries, visit www.oncosolution.com.

Manufacturer Information

Encoraf 75 mg is manufactured under strict international cGMP standards by Everest Pharmaceuticals Ltd., a leading high-tech generic pharmaceutical manufacturer in Bangladesh recognized globally for its high-quality specialized oncology pipelines.